Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).

被引：1
|
作者：
Krantz, Benjamin A.
Tsui, Dana
Lowery, Maeve Aine
Capanu, Marinela
Yu, Kenneth H.
Kelsen, David Paul
Gedvilaite, Erika
Zhang, Liguo
Selcuklu, S. Duygu
You, Daoqi
Pernicka, Jennifer S. Golia
Do, Richard K. G.
Iacobuzio-Donahue, Christine A.
O'Reilly, Eileen Mary
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Trinity Coll Dublin, Dublin, Ireland
[3] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.316
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
316
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).
    Mehdi, Maahum
    Kamgar, Mandana
    George, Ben
    Szabo, Aniko
    Annunzio, Kaitlin
    Taylor, Bradley W.
    Shreenivas, Aditya Varnam
    Chakrabarti, Sakti
    Thomas, James P.
    Tsai, Susan
    Christians, Kathleen K.
    Evans, Douglas B.
    Clarke, Callisia
    Hall, William Adrian
    Erickson, Beth
    Ahmed, Gulrayz
    Thapa, Bicky
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Pilot study of plasma KRAS as a prognostic biomarker in localized pancreas ductal adenocarcinoma (PDAC).
    Krantz, Benjamin A.
    Gedvilaite, Erika
    Chou, Joanne F.
    Capanu, Marinela
    You, Daoqi
    Yu, Kenneth H.
    Varghese, Anna M.
    Iacobuzio-Donahue, Christine A.
    Kelsen, David Paul
    Tsui, Dana
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [3] Identification of plasma metabolites as biomarker candidates for the diagnosis of pancreatic ductal adenocarcinoma (PDAC)
    Mayerle, Julia
    Kalthoff, Holger
    Reszka, Regina
    Kamlage, Beate
    Pilarsky, Christian
    Gruetzmann, Robert
    Schniewind, Bodo
    Weiss, F. Ulrich
    Lerch, Markus M.
    CANCER RESEARCH, 2013, 73 (08)
  • [4] Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC)
    Norton, Carter
    Smith, Jarrod
    Rubnitz, Zach
    Tan, Grace H.
    Nevala-Plagemann, Christopher Duane
    Soares, Heloisa P.
    Garrido-Laguna, Ignacio
    Florou, Vaia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 619 - 619
  • [5] The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
    Wheatley, Roseanna C.
    Valle, Juan W.
    McNamara, Mairead G.
    HEPATOBILIARY SURGERY AND NUTRITION, 2022,
  • [6] Therapeutic benefit of targeting ERK in mutant KRAS in pancreatic ductal adenocarcinoma (PDAC)
    Hayes, Tikvah K.
    Neel, Nicole F.
    Chenard, Melissa
    Yeh, Jen Jen
    Samatar, Ahmed
    Der, Channing J.
    CANCER RESEARCH, 2013, 73
  • [7] Targeting Pancreatic Ductal Adenocarcinoma (PDAC)
    Parrasia, Sofia
    Zoratti, Mario
    Szabo, Ildiko
    Biasutto, Lucia
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2021, 55 (01) : 61 - 90
  • [8] Biomarker potential of collagens linked to fibroblast subtypes in pancreatic ductal adenocarcinoma (PDAC)
    Thorlacius-Ussing, J.
    Jensen, C.
    Karsdal, M.
    Willumsen, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1323 - S1324
  • [9] Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
    Le, Kai
    Wang, Jia
    Zhang, Tao
    Guo, Yifan
    Chang, Hong
    Wang, Siyuan
    Zhu, Bin
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (04): : 422 - 427
  • [10] Pancreatic ductal adenocarcinoma (PDAC) early detection
    Hinestrosa, Juan P.
    Dhani, Harmeet
    Schroeder, Gregor
    Lewis, Jean M.
    Balcer, Heath I.
    Kurzrock, Razelle
    Keith, Dove
    Sears, Rosalie
    Billings, Paul
    CANCER RESEARCH, 2023, 83 (07)
12345